Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Analyst Insight: Justifying A Price Target Following Poor SPAC Reception

Executive Summary

In a discussion with Medtech Insight, analysts at Ladenburg Thalmann argued the case for their LumiraDX $14.75 price target.

You may also be interested in...



LumiraDX Goes Public In SPAC Merger

Investors have been wary of LuminaraDX since its placement on NASDAQ, driving the share price down.

Minute Insight: MeMed Announces Viral/Bacterial Infection Differentiation Results, Commercial Partnership

DiaSorin will distribute MeMed BV, a rapid point-of-care test that can differentiate bacterial and viral infections, under a new commercial agreement.

EU Investment Looks To Regenerate Tissue, As Well As Its Economy

Xeltis, a Netherlands-based company producing cardiovascular implants to stimulate natural regeneration of biological tissue, has received funding from the European Union’s rescue fund.

Topics

Related Companies

UsernamePublicRestriction

Register

MT144653

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel